Efficacy and safety of alirocumab in patients with or without prior coronary revascularization: Pooled analysis of eight ODYSSEY phase 3 trials.
Atherosclerosis（2018）
摘要
Image 1
更多查看译文
关键词
PCSK9,Alirocumab,Cholesterol-lowering drugs,Low-density lipoprotein cholesterol,Coronary revascularization,Cardiovascular risk
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要